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Aim. To report the outcome of a series of patients with chronic venous disease due to incompetence of saphenous trunks
managed by ultrasound guided foam sclerotherapy (UFS).
Patients and methods. A group of 808 patients comprise this series. CEAP clinical class for limbs was C1: 15%, C2:
81%, C3: 0.5%, C4: 2%, C5: 0.2%, C6: 0.4%. UFS using 1% polidocanol (107 limbs), 1% sodium tetradecyl (102 limbs),
3% sodium tetradecyl (900 limbs) was employed to treat incompetent saphenous trunks. In patients with unilateral varices
1 treatment was required in 43% of patients and 2 treatments in 48% of patients to obliterate incompetent saphenous
trunks and varices. For bilateral varices 2 treatments were required in 40% of patients and 3 treatments in 46% of cases.
The clinical outcome and patency of treated veins on duplex ultrasonography was assessed at a mean follow-up interval of
11 months.
Results. A total of 459 limbs were available for assessment at a follow-up interval of 6 months or greater. The CEAP clin-
ical stage was C0:182 limbs, C1: 241, C2: 22, C3: 0, C4: 11, C5: 2, C6:1. The GSV had remained obliterated in 88% of
limbs and the SSV in 82% of limbs. Recurrent venous incompetence following previous surgery was as effectively treated
by UFS as primary incompetence.
Conclusions. This technique is useful in the management of chronic venous disease as an alternative to surgery.
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Surgery for varicose veins is widely used in the UK
but recurrence may be expected in 25e50% of patients
at 5 years.1e4 Surgery leaves scars and may result in
damage to adjacent structures including nerves, lym-
phatics, major arteries and veins.5 Deep vein throm-
bosis and pulmonary embolism occur.6,7 Saphenous
trunks, but not superficial varices, may be obliterated
by radiofrequency obliteration (RF obliteration)8 or
endovenous laser treatment (EVLT).9 Phlebectomy or
sclerotherapy are used to manage the residual varices.
The advantage of using these methods is more rapid
post-operative recovery compared to surgery.
In 1995 Cabrera reported that foam created using
‘physiological gases’ mixed with polidocanol (a deter-
gent sclerosant) was effective in the management of
truncal saphenous incompetence.10 He used ultra-
sound guided injection into saphenous trunks.
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clinical series using this treatment including Frullini
and Cavezzi who reported a series of 453 patients11
and Barrett who reported a series of 100 limbs.12
Cavezzi has subsequently reported a good outcome
in 93% of 194 patients.13 This technique has become
widely used in southern Europe, Australia, New
Zealand, South America and the USA.14 In the UK
one series has been recently reported involving 60
patients comparing surgical treatment with foam scle-
rotherapy combined with sapheno-femoral ligation.15
The aim of this paper is to report the author’s own
series of patients treated by ultrasound guided foam
(UFS) sclerotherapy for the management of chronic
venous disease.
Methods
A total of 808 patients (666 women, 142 men) were
managed by ultrasound guided foam sclerotherapy
for chronic venous disease due to truncal saphenous
incompetence. Patients without truncal incompetence
have been excluded from this series.rved.
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agement of varices in private practice (Thames Valley
Nuffield Hospital, Wexham, Bucks, UK). Patients
were assessed by clinical examination during which
the CEAP clinical stage was recorded and all under-
went colour duplex ultrasonography (Sonoline, Sie-
mens, Germany) using a 5e9 MHz linear transducer.
The author or an assistant trained in venous duplex
ultrasound examination undertook all investigations.
Patients stood during ultrasound examination and
venous reflux was assessed by manual compression
of the calf followed by release. Reverse flow in the
vein under examination exceeding 0.5 seconds indi-
cated venous incompetence.16 The diameter of incom-
petent saphenous veins and perforating veins was
recorded in a computer database. The extent of previ-
ous varicose vein surgery and recurrent varices
shown by duplex ultrasound was also recorded. The
definition of ‘recurrent’ used here is a saphenous
trunk or system where previous junction ligation or
stripping had been carried out. Limbs in which sur-
gery had been carried out to another vein e.g. previ-
ous SSV surgery in a patient with GSV reflux, were
classified as ‘primary GSV reflux’. Incompetence of
the anterior accessory saphenous vein (AASV) in
limbs where previous GSV surgery had been per-
formed was considered to be recurrent reflux accord-
ing to recent anatomical definitions.17
All treatments were carried out in a consulting
room without sedation or general anaesthesia using
techniques based on those published by Cabrera.18
The great saphenous vein (GSV) was canulated with
an 18g IV cannula (Optiva 2, Medex Medical Ltd,
Rossendale, UK) at the level of the knee or just above
with ultrasound guidance. The GSV below the knee
was injected via a 23 g Butterfly needle (Abbot
Ireland, Sligo, Eire). In the small saphenous vein the
cannula was placed in the proximal part of the calf
10e15 cm from the sapheno-popliteal junction. The
distal SSV was injected using a 23 g Butterfly. Correct
positioning of the cannula or Butterfly was confirmed
by the injection of 0.9% saline solution. Saphenous
varices (3 mm diameter or greater) were injected
through either a 23 g Butterfly or 30 g needle attached
to a 2 ml syringe. Transverse ultrasound images of the
veins were used to guide injections.
The Tessari method of preparing foam was used in
which sclerosant and air was mixed in two syringes
connected by a three-way tap.19 The sclerosants
used were either polidocanol (POL e Sclerovein,
Resinag AG, Zurich, Switzerland) and purified so-
dium tetradecyl sulphate (STD e Fibrovein, STD
Pharmaceuticals Ltd, Hereford, UK). POL was used
as a 1% solution to create the foam to treat saphenousEur J Vasc Endovasc Surg Vol 32, November 2006trunks and STD was used as either a 1% or 3% solu-
tion for saphenous trunks. Foam was prepared in a
ratio of 0.5 ml of sclerosant to 1.5 ml of air in keeping
with previous publications.11
Treatment of Patients
The author’s preparation for this clinical series in-
cluded treating 50 patients in clinical trials under
the supervision of an experienced practitioner of ul-
trasound guided foam sclerotherapy. The author also
has 20 years of experience of vascular duplex ultraso-
nography. Patients lay supine during canulation of the
veins and during treatment to minimise the amount of
blood in the vein and to avoid syncope. With all can-
nulae and Butterflies in place the limb to be treated
was elevated to an angle of about 30  to empty the
veins and foam was injected. The progress of foam
was monitored using ultrasound imaging. No specific
measures were taken to avoid foam entering the deep
veins but only 2 ml of foam per injection was given at
a time. The total amount of foam injected in one treat-
ment session was limited to 20 ml in order to avoid
local or systemic complications. Saphenous trunks
were injected first and any residual varices treated
in subsequent sessions. Blood flow in the deep veins
was encouraged after each injection by asking the
patient to perform as series of dorsiflexions at the
ankle in order to minimise the risk of DVT.
Prophylactic heparin was not given routinely in
this series. A small number of patients with duplex
ultrasound evidence of post-thrombotic deep vein
damage was treated. All received a 5 day course of
prophylactic LMWH and none developed a DVT.
Short stretch compression bandaging was applied
to limbs where saphenous trunks and varices had
been injected. Pehahaft cohesive bandage (Pehahaft,
Hartmann, Germany) was used with Velband
(Velband, Johnson & Johnson Medical, Ascot, Berk-
shire,UK) cottonwool padding applied over the saphe-
nous trunks to increase compression. A class 2 medical
compression stocking was measured and applied over
the bandage to secure the bandage (Credelast,
Credenhill, Ilkeston, Derbyshire, UK). Initially bandag-
ing was left in place for 3e5 days but later in the series
this was increased to 10e14 days to minimise the inci-
dence of thrombophlebitis. Treatment sessions were
carried out at intervals of 2 weeks. Duplex ultrasonog-
raphywas used to check the treated veins for complete-
ness of occlusion. Veins containing a substantial
amount of residual thrombus after sclerotherapy were
managed by aspiration using a 19 g needle.
579Chronic Venous Disease Treated by Foam SclerotherapyPatients were invited to return for follow up visits 6
months after treatment. The patients were asked
about symptoms and recurrence of varices. The
CEAP clinical stage was recorded at each visit and du-
plex ultrasonography used to assess the state of occlu-
sion of saphenous trunks and varices. In addition, the
competence of all other saphenous trunks and deep
veins of the thigh and calf were assessed.
Where recurrent or residual reflux was found in
tributaries or trunks, further UFS was used. The diam-
eter of recurrent incompetent saphenous trunks fol-
lowing earlier foam sclerotherapy was much smaller
than at the initial treatment. Subsequent foam sclero-
therapy was no more technically complex than at
the first treatment and usually resulted in obliteration
of the re-treated saphenous trunk. Longer term
follow-up in retreated saphenous trunks has not been
completed. No patient required surgical treatment.
Statistical Analysis
Data are represented by the mean and range for the
age and median and interquartile range for all other
data, which were not normally distributed. Tests of
statistical significance have not been used. These
were not considered appropriate in a clinical series
where differences may have arisen as a consequence
of differences in treatment policy.
Results
A total of 808 patients are included in this series in
whom 1411 limbs were affected by venous disease.
The clinical and duplex ultrasound findings are sum-
marised in Table 1. The overwhelming majority of
limbs were affected by uncomplicated varicose veins
(CEAP C2, n¼ 1154, 81%) attributable to GSV or SSVreflux but patients from all CEAP clinical stages are
included. Some saphenous trunks shown to be incom-
petent on duplex ultrasound were not treated since
they gave rise to few or no varices. In all 1109 limbs
were managed by foam sclerotherapy. A surprisingly
high proportion of patients had undergone previous
surgery for varicose veins in the vessel being treated,
30% of GSVs and 17% of SSVs. Four limbs were
treated in which post-thrombotic deep vein incompe-
tence was found in association with GSV or SSV
reflux.
Table 2 summarises the number of treatments that
were performed in all 808 patients to obliterate incom-
petence trunks and varices. In 99% of patients with
unilateral varices and 92% of bilateral varices 3 treat-
ments were sufficient to obliterate all veins. The me-
dian volume of sclerosant foam required to achieve
this outcome over all sessions was 14 ml (inter-
quartile range, IQR 9e21 ml, range 1 mle72 ml). The
median volume of foam used per limb over all
sessions was 10 ml (IQR 6e14 ml). In treating the
GSV the median volume of foam used was 10 ml
(IQR 6e14 ml) and for the SSV 6 ml (IQR 5e10 ml).
Initially in this series, 1% POL foam was used to
treat saphenous trunks. Later 1% and 3% STD were
employed. The aim of using stronger sclerosants
was to minimise the risk of recanalisation of saphe-
nous trunks. 1% POL was used in 13% of saphenous
veins, 1% STD in 9% and 3% STD in 78%.
Thrombophlebitis occurred in a small number of
patients (5%) and was managed by analgesia, com-
pression and aspiration of thrombus. Calf vein throm-
bosis was confined to isolated gastrocnemius veins or
to part of the posterior tibial vein (10 cases). All re-
solved with compression by stocking or bandage
and exercise without use of anticoagulants. In one
case a short occlusive thrombus arose in the common
femoral vein 2 weeks following treatment of the GSVTable 1. Patients included in study e clinical data
Total number of patients
Men n¼ 142 Mean age: 56 range: 17e95
Women n¼ 666 Mean age: 52 range: 19e91
CEAP stage e limbs with venous disease considered for treatment, total 1411
C1 C2 C3 C4aþC4b C5 C6
212 (15%) 1154 (81%) 6 29 (2%) 3 7
Duplex ultrasound findings in 1109 limbs which were treated by UFS
GSV reflux, alone 766 (69%)
SSV reflux, alone 223 (20%)
GSV and SSV reflux 120 (11%)
Primary GSV reflux 618 Recurrent GSV reflux 267 (30% of GSVs)
Primary SSV reflux 283 Recurrent SSV reflux 60 (17% of SSVs)
Median GSV diameter 5 mm (IQR 4e6), range 1e18 mm
Median SSV diameter 5 mm (IQR 4e6), range 1e12 mmEur J Vasc Endovasc Surg Vol 32, November 2006
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GSV into the femoral vein. This case was managed by
anticoagulation using low molecular weight heparin
and warfarin continued for six months. The occluded
femoral vein recanalised within 4 weeks and at six
months of follow-up no residual scarring or valve
damage could be demonstrated on duplex ultraso-
nography. In two further cases non-occlusive throm-
bus extended from the SFJ and SPJ (one case each)
into the femoral and popliteal vein. The extent of
the thrombus was limited and firmly adherent to the
vein wall. This was managed by compression stock-
ings and exercise whilst monitoring the extent of the
thrombus by duplex ultrasonography. In these cases
the thrombus resolved without further intervention.
No major systemic complication such as anaphy-
laxis, stroke or transient ischaemic attack occurred in
this series. A number of patients (14, 2% of all patients
treated) reported visual disturbance following treat-
ment. Patients with a previous history of migraine
with visual aura were especially at risk of this prob-
lem. The visual aura was precipitated by sclerother-
apy and resolved in most cases within 30 minutes.
Patients experiencing one episode of visual distur-
bance were prone to further episodes. These patients
were managed by inviting them to rest supine for
30 mins following treatment.
Although all patients were invited for follow-up
examinations at 6 months following treatment, by no
means all patients returned despite reminders. In all
459 limbs have been reviewed at 6 months or more
following treatment, average 11 months, range 6e46
months. This includes 363 of 886 GSVs and 141 of
263 SSVs. Figs. 1 and 2 show the CEAP clinical class
before and after sclerotherapy in these limbs. A sub-
stantial improvement in clinical venous disease was
obtained. Duplex examination of the GSVs showed
occlusion had been obtained in 318 of 363 (88%). In
the SSVs occlusion was present in 116 of 141 (83%).
The data in Table 3 show the outcome of treatment
for the GSV and SSV. Where incompetence or varices
arose in a major tributary of the GSV or SSV this
was also considered to comprise treatment failure.
In 4 cases reviewed after 6 months the anterior acces-
sory saphenous vein developed reflux and in one case
a medial thigh tributary of the GSV was incompetent.
Table 2. Number of treatments received per patient
Patient analysis Unilateral varices Bilateral varices
1 treatment 187 (43%) 20 (6%)
2 treatments 207 (48%) 153 (40%)
3 treatments 34 (8%) 173 (46%)
>3 treatments 3 (1%) 31 (8%)Eur J Vasc Endovasc Surg Vol 32, November 2006The data in Table 3 has been subdivided to assess fac-
tors which might influence the outcome including
diameter of the vein, type of sclerosant and whether
primary or recurrent varices were treated. A greater
incidence of recanalisation was seen in GSVs and
SSVs larger than 5 mm in diameter. The recurrence
rates are similar with both sclerosants used in the
treatment. A substantial proportion (30%) of patients
were treated for recurrent varices of the GSV follow-
ing previous surgery. The outcome for this group
was similar to that for patients with primary varices.
Residual skin pigmentation and palpable lumps
were sometimes seen at follow-up. Skin pigmentation
was seen in 115 of 459 limbs at 6 months and palpable
lumps were present in 21 limbs. The skin pigmenta-
tion was almost always of a minor extent and contin-
ued to fade with time. 1 year or more following
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581Chronic Venous Disease Treated by Foam SclerotherapyTable 3. Outcome in 363 (of 886) GSVs and 141 (of 263) SSVs where follow-up had been completed at 6 months or more (mean
11 months following treatment)
Total examined Vein status
Occluded Incompetent
GSV 363 318 (88%) 45
GSV> 5 mm dia 160 130 (81%) 30
GSV<¼ 5 mm dia 203 189 (93%) 15
GSV treated POL 39 33 (80%) 6
GSV treated STD 324 285 (88%) 39
GSV primary 257 220 (86%) 37
GSV recurrent 106 98 (92%) 8
Median diameter Before treatment 5 mm (IQR 4e6) After treatment 2 mm (IQR 0e3)
SSV 141 116 (82%) 25
SSV> 5 mm dia 62 48 (77%) 14
SSV<¼ 5 mm dia 79 68 (86%) 11
SSV treated POL 15 11 (73%) 4
SSV treated STD 126 105 (84%) 21
SSV primary 135 111 (82%) 24
SSV recurrent 6 5 1
Median diameter Before treatment 5 mm (IQR 4e6) After treatment 2 mm (IQR 1e3)treatment skin pigmentation was present in 11 of 115
limbs. Small palpable lumps were sometimes detect-
able in the calf and comprised residual elements
of treated veins. In contrast to surgical series, no
scars, neurological damage or lymphatic injuries
were encountered.
Discussion
The publication of a clinical series cannot replace
a randomised controlled trial (RCT) in the evaluation
of a new treatment. The author acknowledges one
RCT has been published, however both groups of pa-
tients underwent surgical ligation of the SFJ with scle-
rosant foam or stripping being used to manage the
saphenous trunk.15 A further randomised clinical trial
of Varisolve, a polidocanol foam, compared against
surgery in 650 patients has been completed and re-
ported at a scientific meeting (UIP Chapter meeting,
San Diego, USA, 2003) but not yet published. The final
endpoint is the efficacy with which a treatment elim-
inates varicose veins after an extended period of
follow-up. Hobbs found that a follow-up period of
10 years was required fully to distinguish the failures
of injection-compression treatment from surgery.20
Such long studies are difficult to complete and
many authors now base their conclusions on the use
of duplex ultrasound imaging as a surrogate end-
point. There is a good correlation between duplex re-
currence at the SFJ 1 year after treatment and clinical
recurrence 5 years after treatment.21 Duplex ultra-
sonography has been used as a predictor of the final
outcome of treatment in this series.Varicose vein surgery is imperfect. Neurological
injury and an unsatisfactory outcome are common
causes for litigation, damage to the femoral artery
and vein also occurs.5 Rautio found that patients un-
dergoing varicose vein surgery required on average
16 days off work compared to 6.5 days following RF
closure of the saphenous trunk.22 Recurrence of
varicose veins following surgery is a common event
and is often attributable to neovascularisation.21,23,24
Fischer reviewed 125 limbs in 77 patients after an
average of 34 years following SFJ ligation and
GSV stripping and found recurrence in 60%.3 Wood
et al. reported that neurological injury may be present
in 27% of patients treated surgically six weeks post-
operatively.25 Ouvry reports an 8.7% rate of lymphatic
complications amongst 30 surgeons surveyed.26
Surgical treatment which is widely regarded as the
reference standard, carries the risk of significant
post-operative complications, necessitates significant
time off work and despite this does not prevent
recurrence.
In my series foam sclerotherapy required 30 min-
utes per treatment session, patients could walk from
the room afterwards and in most cases patients only
took time off on the days in which treatment was
given. Discomfort at the time of treatment was mini-
mal and in the majority of patients, symptoms in the
2 weeks following treatment were few, although
thrombophlebitis was seen in 5%. Patients main com-
plaints related to the compression bandage applied
after each session. Few other problems were encoun-
tered with skin pigmentation at follow-up being the
most frequent. This was usually mild and continued
to resolve with the passage of time.Eur J Vasc Endovasc Surg Vol 32, November 2006
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sent only 40% of the overall group. This is a potential
disadvantage since it might lead to bias in the overall
assessment. Patients were all invited to attend at an in-
terval of 6 months following initial treatment but
many defaulted. In some instances patients returned
with residual or recurrent varices due to recanalisation
of the treated vein. Further invitations for review have
now been sent to those who have not attended so far at
the planned 6 month interval.
Examination of Table 3 shows that the main factor
influencing recurrence was the size of the vein prior
to treatment. Both GSVs and SSVs of 6 mm dia or
greater were more likely to recur than those of 5 mm
dia and below. For the GSV, treatment of recurrent
varicose veins was as successful as for primary vari-
ces. Operations for recurrent varicose veins are usu-
ally technically more difficult and prone to a high
complication rate compared to that for primary vari-
ces.27 Foam sclerotherapy carries little risk and may
be a satisfactory solution in patients with recurrence
following previous surgery.
In the series of patients presented here, no case of
neovascularisation was seen at the SFJ or SPJ although
this would have been expected following surgical
treatment. The mode of recurrence following UFS
was recanalisation of previously treated veins. It is
likely that surgical treatment itself promotes neovas-
cularisation. If varicose veins can be closed without
surgical intervention then the risk of neovascularisa-
tion is minimised.
Comparison of UFS to other endovenous techniques
reveals similar outcomes. In a series of 1006 patients
treated by RF obliteration with follow-up to 5 years
the occlusion rate for saphenous trunks was 88% at
one year.28 Endovenous laser treatment (EVLT) been
reviewed recently.29 In 13 clinical series 88e100% of
treated saphenous trunks were obliterated. Reported
complications of both techniques include skin burns,
thrombosis, ecchymosis, paraesthesia, induration and
phlebitis.
This clinical series demonstrates that ultrasound
guided foam sclerotherapy can be used effectively to
manage a wide range of chronic venous disease on
an outpatient basis without the need to resort to sur-
gical intervention. The efficacy and rates of complica-
tion are similar to those reported for the other ‘new’
treatments for varicose veins.
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